How much profit has Passage Bio made this year?
Passage Bio has made -41.46 M USD this year.
Passage Bio Net Income 2025
Passage Bio Net Income
-41.46 M USD
Ticker
PASG
ISIN
US7027121000
WKN
A2P0EQ
In 2025, Passage Bio's profit amounted to -41.46 M USD, a -31.03% increase from the -60.11 M USD profit recorded in the previous year.
The Passage Bio Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2029e | 169.17 |
| 2028e | 70.57 |
| 2027e | -4.1 |
| 2026e | -46.73 |
| 2025e | -41.46 |
| 2024e | -60.11 |
| 2023 | -102.06 |
| 2022 | -136.13 |
| 2021 | -185.39 |
| 2020 | -112.23 |
| 2019 | -45.63 |
| 2018 | -12.77 |
Passage Bio Revenue, EBIT, Net Income US7027121000 · A2P0EQ
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Passage Bio, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Passage Bio from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Passage Bio’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Passage Bio. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Passage Bio’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Passage Bio’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Passage Bio’s growth potential.
Passage Bio Revenue, EBIT and net profit per share
| Date | Passage Bio Revenue | Passage Bio EBIT | Passage Bio Net Income |
|---|---|---|---|
| 2029e | 262.7 M undefined | 115.06 M undefined | 169.17 M undefined |
| 2028e | 119.93 M undefined | 5.88 M undefined | 70.57 M undefined |
| 2027e | 34.43 M undefined | -51.74 M undefined | -4.1 M undefined |
| 2026e | 408,000 undefined | -78.64 M undefined | -46.73 M undefined |
| 2025e | 0 undefined | -67.67 M undefined | -41.46 M undefined |
| 2024e | 0 undefined | -71.63 M undefined | -60.11 M undefined |
| 2023 | 0 undefined | -103 M undefined | -102.06 M undefined |
| 2022 | 0 undefined | -138.39 M undefined | -136.13 M undefined |
| 2021 | 0 undefined | -185.73 M undefined | -185.39 M undefined |
| 2020 | 0 undefined | -112.9 M undefined | -112.23 M undefined |
| 2019 | 0 undefined | -37.19 M undefined | -45.63 M undefined |
| 2018 | 0 undefined | -13.47 M undefined | -12.77 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2018 | 0 USD | -13.47 M USD | -12.77 M USD |
| 2019 | 0 USD | -37.19 M USD | -45.63 M USD |
| 2020 | 0 USD | -112.9 M USD | -112.23 M USD |
| 2021 | 0 USD | -185.73 M USD | -185.39 M USD |
| 2022 | 0 USD | -138.39 M USD | -136.13 M USD |
| 2023 | 0 USD | -103 M USD | -102.06 M USD |
| 2024e | 0 USD | -71.63 M USD | -60.11 M USD |
| 2025e | 0 USD | -67.67 M USD | -41.46 M USD |
| 2026e | 408,000 USD | -78.64 M USD | -46.73 M USD |
| 2027e | 34.43 M USD | -51.74 M USD | -4.1 M USD |
| 2028e | 119.93 M USD | 5.88 M USD | 70.57 M USD |
| 2029e | 262.7 M USD | 115.06 M USD | 169.17 M USD |
Passage Bio stock margins US7027121000 · A2P0EQ
The Passage Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Passage Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Passage Bio.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Passage Bio's sales revenue. A higher gross margin percentage indicates that the Passage Bio retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Passage Bio's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Passage Bio's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Passage Bio's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Passage Bio. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Passage Bio's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Passage Bio Margin History
| Passage Bio Gross margin | Passage Bio Profit margin | Passage Bio EBIT margin | Passage Bio Profit margin |
|---|---|---|---|
| 2029e | 0 % | 43.8 % | 64.4 % |
| 2028e | 0 % | 4.9 % | 58.84 % |
| 2027e | 0 % | -150.3 % | -11.9 % |
| 2026e | 0 % | -19,274.25 % | -11,453.24 % |
| 2025e | 0 % | 0 % | 0 % |
| 2024e | 0 % | 0 % | 0 % |
| 2023 | 0 % | 0 % | 0 % |
| 2022 | 0 % | 0 % | 0 % |
| 2021 | 0 % | 0 % | 0 % |
| 2020 | 0 % | 0 % | 0 % |
| 2019 | 0 % | 0 % | 0 % |
| 2018 | 0 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2018 | 0 % | 0 % | 0 % |
| 2019 | 0 % | 0 % | 0 % |
| 2020 | 0 % | 0 % | 0 % |
| 2021 | 0 % | 0 % | 0 % |
| 2022 | 0 % | 0 % | 0 % |
| 2023 | 0 % | 0 % | 0 % |
| 2024e | 0 % | 0 % | 0 % |
| 2025e | 0 % | 0 % | 0 % |
| 2026e | 0 % | -19,274.25 % | -11,453.24 % |
| 2027e | 0 % | -150.3 % | -11.9 % |
| 2028e | 0 % | 4.9 % | 58.84 % |
| 2029e | 0 % | 43.8 % | 64.4 % |
Passage Bio Aktienanalyse
What does Passage Bio do?
Passage Bio Inc is a biopharmaceutical company focused on the treatment of rare genetic diseases. The company is headquartered in Pennsylvania, USA and was founded in 2018. The beginnings of Passage Bio Inc can be traced back to the work of the Penn Medicine Gene Therapy Program, which has been focusing on researching gene therapies for rare diseases for many years. In 2018, the company was finally founded to bring the research results to the market and help patients with rare diseases. Passage Bio's business model is to develop and market gene therapies based on AAV (Adeno-associated viruses). These viruses are injected into the body and are used to transport healthy genes into cells to replace defective or diseased genes. This can restore the production of missing or damaged proteins, which can contribute to symptom relief and disease cure. The company specializes in developing gene therapies for rare, monogenic diseases that are often caused by a single genetic defect. Such diseases are often difficult to treat and have no effective therapies. Therefore, gene therapies can be a promising option to help patients with these diseases. Passage Bio currently has four gene therapy candidates in its pipeline, all focusing on rare neurological diseases. The first candidate, PBGM01, aims to treat GM1 gangliosidosis, a genetic disorder that leads to impairment of the nervous system and often severe impairment of intellectual and physical development. The other candidates focus on treating diseases such as Krabbe disease, frontotemporal dementia, and Niemann-Pick disease type A. Passage Bio has also partnered with Catalent to support the manufacturing and packaging of its gene therapy products. The two companies are working together to develop a scalable production platform for gene therapy manufacturing, which will enable Passage Bio to produce and distribute therapies on a large scale. Overall, Passage Bio has the potential to change the lives of many patients with rare diseases. By developing gene therapies based on AAV technology, the company can create a promising therapy option for patients who currently have no other options available. With a dedicated team of researchers and development specialists, the company is working hard to develop new gene therapies that can contribute to the relief and cure of rare and serious diseases. Passage Bio ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Passage Bio's Profit Margins
The profit margins of Passage Bio represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Passage Bio's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Passage Bio's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Passage Bio's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Passage Bio’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Passage Bio stock
How has the profit developed compared to last year?
The profit has increased by -31.03% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Passage Bio publish its earnings?
Passage Bio publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Passage Bio?
The profits of Passage Bio are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Passage Bio?
You can learn more about the earnings of Passage Bio by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Passage Bio pay?
Over the past 12 months, Passage Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Passage Bio is expected to pay a dividend of 0 USD.
What is the dividend yield of Passage Bio?
The current dividend yield of Passage Bio is .
When does Passage Bio pay dividends?
Passage Bio pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Passage Bio?
Passage Bio paid dividends every year for the past 0 years.
What is the dividend of Passage Bio?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Passage Bio located?
Passage Bio is assigned to the 'Health' sector.
Wann musste ich die Aktien von Passage Bio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Passage Bio from 1/20/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/20/2025.
When did Passage Bio pay the last dividend?
The last dividend was paid out on 1/20/2025.
What was the dividend of Passage Bio in the year 2024?
In the year 2024, Passage Bio distributed 0 USD as dividends.
In which currency does Passage Bio pay out the dividend?
The dividends of Passage Bio are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Passage Bio
Our stock analysis for Passage Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Passage Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
